Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose cyproheptadine for BMI improvement in underweight children
IRCT20240213060992N1Phase 4Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cyproheptadine in Underweight (3 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Height, Weight and 2 more. Started Jul 2024; status: completed.
02
Drugs
cyproheptadine
03
Conditions
Underweight
Beyond the preview
Go deeper on IRCT20240213060992N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240213060992N1.